The median OS was not evaluable, though the estimated 2-year OS rate was 78.7%.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
Treatment chart with usual dosage, strength, and formulation of FDA approved medications for breast cancer.
As the report covers only 3 of 1000 known BRCA variants, a negative result does not mean an individual is at a lower cancer risk.
A variety of viruses are being researched in cancers including melanoma, brain tumors, breast cancers, and others.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
Abemaciclib was previously approved for HR-positive, HER2-negative metastatic breast cancer either alone or in combination with fulvestrant following disease progression.
The 5-year DFS rates were 90.0% for patients receiving anastrozole, 88.0% for exemestane, and 89.4% for letrozole.
Breast cancer screening using MRI versus mammography associated with more biopsies but lower cancer yieldFebruary 21, 2018
1. In women both with and without personal history of breast cancer (PHBC), screening MRI was associated with higher biopsy rates compared to mammography. 2. Screening MRI was also associated with lower rates of ductal carcinoma in situ (DCIS) and invasive cancer findings when compared to mammography. Evidence Rating Level: 2 (Good) Study Rundown: Screening 
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
It was previously unknown whether patients with ER-positive disease would benefit from adjuvant chemotherapy.
Metronomic Chemotherapy May Improve Outcomes Among Elderly Patients With HER2-Positive Breast CancerFebruary 12, 2018
Researchers evaluated whether dual HER2 inhibition with trastuzumab and pertuzumab plus metronomic cyclophosphamide is superior to dual HER2 inhibition alone.
Epidemiologic data of flaxseed dietary intake and high enterolactone serum concentrations suggest that flaxseed consumption may reduce the risk of breast cancer.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Researchers evaluated whether neoadjuvant SB3 would show an equivalent pathologic complete response rate in primary breast tumors to trastuzumab among patients with HER2-positive disease.
Investigators assessed the outcomes of 118 patients with AR-positive locally advanced or metastatic TNBC who received enzalutamide 160 mg once daily.
Novel algorithms may be able to diagnose and plan cancer treatments more effectively than humans, but it's unclear if and when artificial intelligence will be integrated into clinical practice.
Researchers found that MSK1 is a key regulator of latency.
While APHINITY showed a small improvement with adjuvant pertuzumab, it is unclear whether the benefits are worth the cost, time, and toxicity associated with the drug.
Olaparib was previously granted Priority Review designation by the FDA.
While patients treated with nab-paclitaxel did have a marginally higher pCR rate, this improvement was not significant.
Get the latest breast cancer treatment regimens with in-depth drug information on therapies such as tamoxifen, trastuzumab, and docetaxel.
There is no evidence that women at high risk of breast cancer, such as those who harbor BRCA1 or BRCA2 mutations, should avoid hormonal contraception.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
Without accounting for the time period in which the decision was made, the concordance rate between Watson and the tumor board was 73%.
A clinical objective response was noted in 95% of patients prior to surgery; 27% of patients had a pathological complete response in the breast and axillary nodes.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma